Facebook      Twitter




2011 HIV Treatment Guidelines Overview: When and What to Start, and Long-Term Quality Outcomes (13HC03)

Tameka Simpson, DO; Sindy M. Paul, MD, MPH, FACPM; Debbie Y. Mohammed, MS, MPH, APRN-BC


Release Date: June 1, 2011
Expiration Date: May 30, 2013
Activity Code: 13HC03

To receive CE credit you should:

  • Review the activity in its entirety
  • Successfully complete the post-test
  • Submit an activity evaluation

Upon successful completion of these requirements, you will have access to a printable credit statement.

If you have any questions about this process, please email the Center for Continuing and Outreach Education at ccoereg@ca.rutgers.edu or call CCOE Enrollment Services at (800) 227-4852.

As seen in the June 2011 edition of



Sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ), Center for Continuing & Outreach Education (CCOE), Division of AIDS Education.


This activity is supported by an educational grant from the New Jersey Department of Health and Senior Services (NJDHSS) – Division of HIV, STD and TB Services, through an MOA, “Education and Training for Physicians and other Healthcare Professionals in the Diagnosis and Treatment of HIV/AIDS.”

Target Audience

This free knowledge-based activity is designed for physicians, nurses, pharmacists, social workers, and other health care professionals in New Jersey who are involved in the care of persons with HIV/AIDS and/or tuberculosis.

Statement of Need

The CDC and Infectious Disease Society of America (IDSA) published updated HIV treatment guidelines on January 10, 2011, with a focus on the selection and timing of initial antiretroviral treatment (ART) regimen for treatment-naiive patients. Several agents are classified as “alternative” or “acceptable,” due to adverse effects, and maraviroc was added following favorable clinical trial results. The guidelines panel found sufficient observational data to recommend extension of ART, previously recommended at a CD4 level of 350, to those with CD4 counts between 350-500 cells/mm3. However, the risks of non-adherence, including ART resistance, may be greater than the potential benefit of treatment, if the patient has not been adequately engaged in care. Clinicians should assess patient readiness for treatment before initiating ART, to increase adherence and improve treatment outcomes. The HRSA-HIV/AIDS Bureau quality benchmarks are an important tool to track clinician and practice adherence to best practices of adherence education and counseling, screening for opportunistic infections and other health markers, and laboratory monitoring.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Identify factors that should be incorporated in the decision to start antiretroviral therapy, including appropriate timing.
  2. Describe the new recommended initial combination regimens for antiretroviral-naïve patients.
  3. Implement current performance measures used in tracking quality long-term outcomes.


Activity Director(s)/CME Academic Advisor(s)

Patricia Kloser, MD, MPH, Professor of Medicine, UMDNJ-New Jersey Medical School.

Planning Committee

Sindy Paul, MD, MPH, FACPM, Medical Director, Division of HIV, STD and TB Services, New Jersey Department of Health and Senior Services.

Debbie Y. Mohammed, MS, MPH, APRN-BC, ACRN, Nurse Practitioner, UMDNJ-University Hospital and St.Michael’s Medical Center – Peter Ho Clinic.

Humberto Jimenez, PharmD, AAHIVE, Infectious Disease Pharmacist, St.Michael’s Medical Center; Clinical Assistant Professor, Ernest Mario School of Pharmacy, Rutgers University.

Kimi Nakata, MSW, MPH, UMDNJ-CCOE-Division of AIDS Education Program Supervisor and Editor, NJ AIDSLine.

Bonnie R. Abedini, MSN, RN, Director, Quality & Compliance, Rutgers University Health Services.

Method of Instruction

Participants should read the learning objectives and review the activity in its entirety. After reviewing the material, complete the self-assessment test which consists of a series of multiple-choice questions. Upon achieving a passing score of 70% or more on the self-assessment test, and submitting a course evaluation, participants will have access to an online printable credit statement.Estimated time to complete this activity as designed is 1.5 hours for physicians, 1.01 hours for nurses, and 0.75 hours for pharmacists.


UMDNJ–Center for Continuing and Outreach Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

UMDNJ–Center for Continuing and Outreach Education designates this educational activity for a maximum of 1.5 hours of AMA PRA category credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

UMDNJ-Center for Continuing and Outreach Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This course (ACPE #0374-0000-11-003-H02-P) qualifies for 0.75 contact hours (0.125 CEU) of continuing pharmacy education credit.

Pharmacists and nurses should only claim those contact hours actually spent participating in the activity.

UMDNJ-Center for Continuing Education andOutreach Education is an approved provider of continuing nursing education by NJSNA, an accredited approver, by the American Nurses Credentialing Center’s Commission on Accreditation. Provider Number P173-11/09-12. Provider Approval is valid through November 30, 2012.

This activity is awarded 1.01 contact hours. (60 minute CH)

Nurses should only claim those contact hours actually spent participating in the activity.

Provider approved by the California Board of Registered Nursing, Provider Number CEP 13780.

Approved provider status refers only to continuing education activities and does not imply ANCC COA or NJSNA endorsement of any commercial products.

UMDNJ-CCOE certifies that this continuing education offering meets the criteria for up to 0.1 Continuing Education Units (CEUs), provided the activity is completed as designed. One CEU equals 10 contact hours of participation in an organized continuing education experience under responsible sponsorship, capable direction and qualified instruction. Participants should only claim those contact hours actually spent participating in the activity.


In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, UMDNJ-CCOE has resolved all potential and real conflicts of interest through content review by non-conflicted, qualified reviewers. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by Patricia Kloser, MD, MPH; Humberto Jimenez, PharmD, AAHIVE; and Brenda Christian, MEd, PA-C; UMDNJ-CCOE Director of AIDS Education.

Field Test:
This activity was pilot-tested for time required for participation by Kinshasa Morton, MD; Shobha Swaminathan, MD; Jojy Cheriyan, MD; Mary C. Krug, MSN, APN; Renee Powell, BS, RN; Kara Winslow, BSN, RN; Polly Jen, PharmD; John Faragon, PharmD, AAHIVE; and George Rusuloj, PharmD.

Disclosure Disclaimer

In accordance with the disclosure policies of UMDNJ and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/ device not yet approved.

Faculty Disclosure Declarations

There were no relevant financial relationships to disclose reported by the activity director, faculty, planning committee members, peer reviewers or field testers.

Off-Label Usage Disclosure

This activity does not contain information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved.

Content Disclaimer

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of NNDHSS - Division of HIV, STD and TB Services, any manufacturer of pharmaceuticals or devices, or UMDNJ. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.

Copyright © 2011 UMDNJ-Center for Continuing and Outreach Education. All rights reserved including translation into other languages.No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from UMDNJ-Center for Continuing and Outreach Education. Please direct CME related questions to UMDNJ at 973-972-4267 or email ccoe@ca.rutgers.edu.


© Copyright 2018, Rutgers, The State University of New Jersey, an equal opportunity, affirmative action institution.

Privacy Policy